Xtandi - (40 mg; Capsule, Oral)

Generic Name	Enzalutamide	**Innovator**	Astellas
Dosage	40 mg; Capsule, Oral	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	None	**Generic Launches**	None
Indication	It is used to treat men with a certain type of prostate cancer. This type of prostate cancer has not responded to other treatments to lower the male hormone testosterone and has also spread to other parts of the body.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Xtandi - (40 mg, 80 mg Tablet)

Generic Name	Enzalutamide	Innovator	Astellas
Dosage	40 mg, 80 mg Tablet	Branded US Sales	More Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	None		
Complexities	No		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Xtandi - (120 mg and 160 mg ; Tablet)

Generic Name	Enzalutamide	Innovator	Astellas
Dosage	120 mg and 160 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	None		
Complexities	No		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.